CG Oncology, Inc.
CGON
$75.03
$0.320.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 1,982.69% | 409.21% | 3,774.42% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1,982.69% | 409.21% | 3,774.42% | -- |
| Cost of Revenue | 86.98% | 69.99% | 23.24% | 50.14% | 69.63% |
| Gross Profit | -83.28% | -66.37% | -16.56% | -41.96% | -70.66% |
| SG&A Expenses | 66.43% | 40.51% | 53.73% | 167.71% | 132.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.64% | 59.67% | 32.51% | 86.30% | 87.73% |
| Operating Income | -77.27% | -57.30% | -27.99% | -80.70% | -88.53% |
| Income Before Tax | -90.84% | -74.74% | -29.91% | -114.69% | -119.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.84% | -74.74% | -29.91% | -114.69% | -119.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.84% | -74.74% | -29.91% | -114.69% | -119.16% |
| EBIT | -77.27% | -57.30% | -27.99% | -80.70% | -88.53% |
| EBITDA | -76.09% | -55.40% | -25.76% | -79.36% | -87.98% |
| EPS Basic | -64.91% | -57.52% | -12.05% | -87.86% | -91.64% |
| Normalized Basic EPS | -64.91% | -57.54% | -12.06% | -87.89% | -91.60% |
| EPS Diluted | -64.91% | -57.52% | -12.05% | -87.86% | -91.64% |
| Normalized Diluted EPS | -64.91% | -57.54% | -12.06% | -87.89% | -91.60% |
| Average Basic Shares Outstanding | 15.71% | 10.93% | 15.94% | 14.28% | 14.37% |
| Average Diluted Shares Outstanding | 15.71% | 10.93% | 15.94% | 14.28% | 14.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |